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Objectives This study sought to examine patterns of follow-up invasive coronary angiography (ICA) and revascularization
(REV) after coronary computed tomography angiography (CCTA).
Background CCTA is a noninvasive test that permits direct visualization of the extent and severity of coronary artery disease
(CAD). Post-CCTA patterns of follow-up ICA and REV are incompletely defined.
Methods We examined 15,207 intermediate likelihood patients from 8 sites in 6 countries; these patients were with-
out known CAD, underwent CCTA, and were followed up for 2.3  1.2 years for all-cause mortality. Coro-
nary artery stenosis was judged as obstructive when 50% stenosis was present. A multivariable logistic
regression was used to estimate ICA use. A Cox proportional hazards model was used to estimate all-cause
mortality.
Results During follow-up, ICA rates for patients with no CAD to mild CAD according to CCTA were low (2.5% and
8.3%), with similarly low rates of REV (0.3% and 2.5%). Most ICA procedures (79%) occurred 3 months of
CCTA. Obstructive CAD was associated with higher rates of ICA and REV for 1-vessel (44.3% and 28.0%),
2-vessel (53.3% and 43.6%), and 3-vessel (69.4% and 66.8%) CAD, respectively. For patients with 50%
stenosis, early ICA rates were elevated; over the entirety of follow-up, predictors of ICA were mild left main,
mild proximal CAD, respectively, or higher coronary calcium scores. In patients with 50% stenosis, the
relative hazard for death was 2.2 (p  0.011) for ICA versus no ICA. Conversely, for patients with CAD, the
relative hazard for death was 0.61 for ICA versus no ICA (p  0.047).
Conclusions These findings support the concept that CCTA may be used effectively as a gatekeeper to ICA. (J Am Coll
Cardiol 2012;60:2103–14) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.05.062
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Computed Tomography Angiography as Gatekeeper November 13, 2012:2103–14Stress testing and the provoca-
tion of inducible ischemia have
been the mainstay of cardiac di-
agnostic testing but have limita-
tions because of a diminished di-
agnostic accuracy when compared
with the gold standard of invasive
coronary angiography (ICA). In a
recent report from the American
College of Cardiology’s National
Cardiovascular Data Registry,
the rate of nonobstructive coro-
nary artery disease (CAD) was
exceedingly high—59%—for pa-
tients with a positive functional test
before undergoing ICA (1). Coro-
nary computed tomographic an-
giography (CCTA) has emerged
as a noninvasive, diagnostic im-
aging modality that directly vis-
ualizes the coronary anatomy with a
reportedly high diagnostic accu-
racy (2–5). Given the high accuracy of CCTA compared
with conventional stress testing, it remains plausible that
CCTA may more effectively identify patients with CAD
who are more often candidates for ICA and who might
benefit from revascularization (REV). However, few reports
have examined post-CCTA management.
In 2008, the Centers for Medicare and Medicaid Services
(CMS) completed its review of the scientific evidence
concerning CCTA and indicated that no national coverage
determination was appropriate because of a paucity of
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Manuscript received April 21, 2012; accepted May 1, 2012.evidence in certain indications (6,7). After careful review
of the published evidence, the panel ranked the ability of
CCTA to act as a gatekeeper to ICA or in replacement of
ICA as “unsure” (7). Since then, ongoing observational
evidence has been accruing, including the development of
and initial publications from the CONFIRM (Coronary
CT Angiography Evaluation for Clinical Outcomes: An
International Multicenter) registry (8–12). One of the main
goals of the CONFIRM registry was to evaluate post-
CCTA utilization patterns and to evaluate the role of
CCTA as a gatekeeper to downstream ICA and coronary
REV Moreover, given the national coverage determination
by CMS (7), a secondary aim was to examine the impact of
CCTA evidence on downstream resource utilization in a
population generalizable to Medicare beneficiaries (i.e.,
elderly patients enrolled in the CONFIRM registry).
Methods
Enrollment criteria. Details of the CONFIRM registry
design and data elements have been published (8–11).
Inclusion criteria for this subset of patients were those
referred for suspected CAD. Patients were excluded from
the study if they had a prior diagnosis of myocardial
infarction, catheterization-defined CAD, or prior REV.
Thus the remaining CONFIRM cohort included a total of
15,207 patients. A total of 8 sites from 6 countries partic-
ipated in this substudy. All participating sites enrolled a
consecutive series of patients who were prospectively followed
up for the occurrence of death from all causes, for ICA, or for
REV. Each site had institutional review board approval for all
registry procedures, including follow-up methodologies.
Clinical history data. Uniform data collection methods
were applied at all participating sites. Each site systemati-
cally collected data on each consecutive patient, applying
standardized definitions for suspected cardiac symptoms,
risk factors, and angiographic CAD extent and severity. The
CONFIRM design article contains detailed information on
this case report form and data collection methodologies (8). In
rief, data were collected on traditional cardiac risk factors,
ncluding hypertension, diabetes, dyslipidemia, current smok-
ng, and a family history of premature CAD. Patients treated
or or with a prior diagnosis of hypertension, diabetes, or
yslipidemia, respectively, were categorized as having that risk
actor. A family history of premature CAD was defined as a
rimary relative with a diagnosis early in life (i.e., mother65
ears of age or father 55 years of age). The presence of
xcessive dyspnea was recorded. Chest pain was categorized by the
nterviewing physician as nonanginal, atypical angina, or typical
ngina. A pretest CAD likelihood was calculated using the
atient’s age, sex, and typicality of chest pain symptoms (13).
CTA protocol and interpretation. Standardized proto-
ols for image acquisition as defined by the Society of Cardio-
ascular Computed Tomography were used at all participating
ites. Specific details of the CCTA procedures have been
efined in detail elsewhere (8–11).
4se, CCB
2105JACC Vol. 60, No. 20, 2012 Shaw et al.
November 13, 2012:2103–14 Computed Tomography Angiography as GatekeeperEach site applied the standard anatomic segmental
analysis for image interpretation. All segments were
coded for the presence and severity of coronary stenosis
and graded for or using a 7-point scoring system (0 
none, 1  1% to 24%, 2  25% to 49%, 3  1% to 49%,
 50% to 69%, 5  70% to 99%, and 6  100%). Some
sites used a scoring of 25% to 49%, whereas others used
a score of 1% to 49%. For this analysis, “no CAD” was
defined as a score of 0 in all major epicardial arteries.
Mild CAD was defined as a score of 1 to 3. CAD extent
was coded as the number of vessels with 50% stenosis
and was categorized as none, 1-vessel, 2-vessel, and
3-vessel/left main CAD, respectively.
Coronary artery calcium (CAC) scoring was performed in a
subset of 10,754 patients. The methods for CAC scoring have
been previously published (10). CAC scores were categorized
as 0, 1 to 10, 11 to 99, 100 to 399, and 400, respectively.
Clinical Characteristics of the CONFIRM RegistSuspected CAD Cohort (n  15,207)Table 1 Clinical Charact ristics of the CONSuspected CAD Cohort (n  15,20
None
(n  7,028)
Mild CAD
(n  5,380)
1-Ve
(n
Age (yrs)
40 14.1% 2.2%
40–49 26.9% 14.2%
50–59 32.1% 30.8%
60–69 21.5% 34.9%
70–79 4.9% 15.6%
80 0.6% 2.2%
Female 54.6% 39.6%
Any chest pain
None 32.9% 43.6%
Noncardiac 8.1% 8.7%
Atypical 50.3% 39.3%
Typical 8.8% 8.4%
Dyspnea 23.2% 26.5%
Pre-test likelihood
Very low 35.5% 22.2%
Low 25.0% 32.7%
Intermediate 34.5% 39.1%
High 5.0% 6.0%
Previous stress test 47.8% 48.7%
Obesity (kg/m2) 22.0% 25.6%
Hypertension 41.0% 51.1%
Diabetes mellitus 8.8% 14.3%
Dyslipidemia 47.5% 58.5%
Family history of CAD 27.5% 29.6%
Medication use
Aspirin 29.1% 43.9%
Beta-blockers 24.2% 33.8%
CCB 18.2% 26.2%
ACE inhibitors 11.3% 19.8%
Nitrates 10.1% 10.4%
Statins 21.6% 39.6%
Insulin 0.6% 2.1%
ACE  angiotensin converting enzyme; CAD  coronary artery disea
Evaluation for Clinical Outcomes: An International Multicenter registry.Follow-up methods. All patients were prospectively fol-
lowed up for a mean of 2.3  11.2 years (range 0.01 to 6.2
years). The occurrence of all-cause death was ascertained by
study personnel or by querying of national medical data-
bases. Secondary endpoints included a: hospital stay for an
acute coronary syndrome (ACS) or myocardial infarction
(MI). Standardized definitions for ACS/MI were used. An
ACS hospital stay was defined as the occurrence of unstable
angina symptoms with electrocardiographic changes. For an
acute MI, biomarker confirmation also was confirmed
during the hospital stay. Additional details on the methods
used to ascertain clinical endpoints have been published
previously (8–10,12,14). Detailed information on the oc-
currence and date of follow-up ICA or REV was collected.
All patients were queried using a scripted interview, and all
procedures were confirmed by review of each patient’s
medical records. A total of 99 patients (0.8%) were lost to
Registry
AD
3)
2-Vessel CAD
(n  705)
3-Vessel CAD/Left Main
(n  381) p Value
0.0001
1.0% 0.3%
8.2% 5.8%
27.2% 23.4%
37.2% 39.4%
22.0% 24.1%
4.4% 7.1%
26.7% 24.2% 0.0001
0.0001
36.7% 34.1%
10.0% 11.3%
34.4% 32.4%
18.9% 22.3%
28.5% 28.1% 0.0001
0.0001
14.2% 9.9%
29.9% 29.9%
41.8% 44.0%
14.1% 16.2%
49.9% 50.3% 0.82
26.9% 25.9% 0.0001
61.4% 67.6% 0.0001
23.6% 23.9% 0.0001
69.1% 69.0% 0.0001
40.4% 40.9% 0.0001
55.2% 54.7% 0.0001
43.9% 42.6% 0.0001
25.5% 19.1% 0.0001
26.7% 32.4% 0.0001
13.4% 11.7% 0.0001
58.3% 61.6% 0.0001
0.7% 2.9% 0.0001
 calcium channel blocker; CONFIRM  Coronary CT AngiographyryFIRM
7)
ssel C
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1.1%
10.6%
28.4%
36.3%
20.0%
3.6%
34.5%
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7.6%
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15.9%
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30.9%
41.0%
11.5%
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presented herein.
Statistical methods. We compared categorical variables by
he presence and extent of obstructive CAD according to
CTA using a likelihood ratio or linear-by-linear associa-
ion chi-square statistic. The frequency of patients and their
nsuing clinical characteristics undergoing ICA use with
nd without REV was calculated. A multivariable logistic
egression model was used to estimate clinical and angio-
raphic variables associated with follow-up ICA use. The
dds ratio and 95% confidence intervals were calculated.
odel statistics including classification results were calcu-
ated. Model overfitting procedures were considered by
imiting 1 variable in the multivariable model for every 10
ncident dependent outcomes. Significant colinearity was
voided by limiting inclusion of variables with a correlation
0.8. A similar logistic regression model was applied to
xamine estimators of early ICA occurring within 90 days of
CTA. A final multivariable logistic regression model
ncluded estimators of ICA use for patients with CCTA
efined as 50% stenosis. For these models, the enrolling
ite was not a multivariable predictor. Using the methods of
cNeill, a receiver operating characteristics (ROC) curve
as used to estimate ICA and REV use by including the
Clinical Characteristics of Patients UndergoingICA With and Without C ron ry REV Aft r CCTATable 2 Clinical Characte istics of Patie tsICA With and Without Coronary REV
No ICA
(n  13,327)
ICA
(n  1,896
Age deciles (yrs)
40 8.3% 1.2%
40–49 20.4% 10.8%
50–59 31.1% 28.6%
60–69 27.8% 38.1%
70–79 10.7% 18.1%
80 1.7% 3.2%
Female 46.2% 35.8%
Chest pain
None 38.0% 35.1%
Noncardiac 8.4% 8.8%
Atypical 44.5% 38.2%
Typical 9.1% 17.9%
Dyspnea 25.1% 25.8%
Pre-test likelihood
Very low 28.8% 15.3%
Low 28.7% 28.8%
Intermediate 36.6% 43.3%
High 5.9% 12.7%
Prior stress test 47.9% 50.5%
Obesity 23.6% 26.5%
Hypertension 47.1% 55.3%
Diabetes mellitus 12.0% 19.8%
Current smoker 16.3% 17.6%
Dyslipidemia 53.4% 66.0%
Family history of CAD 28.5% 39.9%CAD  coronary artery disease; CCTA  coronary computed tomo
REV  revascularization.pretest CAD likelihood variable along with the CCTA-
defined CAD, whereby areas were compared using an
asymptotic p value calculation (15).
We calculated the time to downstream ICA and REV
using a Cox proportional hazards survival model. The
median (interquartile range) time to ICA was 0.05 (0.01 to
0.20) years. For persons undergoing ICA, the median
(interquartile range) time to percutaneous coronary inter-
vention was 1.4 (0.08 to 2.4) years; it was 2.0 (1.3 to 3.2)
years for time to coronary artery bypass surgery.
Adjusted survival also was calculated using a stratified
Cox proportional hazards regression model using the pri-
mary endpoint of time to all-cause death. In every case, the
proportional hazards assumptions were met. We considered
model overfitting by limiting our multivariable model to only
1 variable for every 10 deaths. A total of 185 deaths were
observed in this patient cohort. We a priori identified several
clinical covariates to include in the multivariable model, in-
cluding age, symptoms, and cardiac risk factors. The Cox
models were stratified by CCTA-defined CAD to examine
differences in survival by ICA and REV. We further compared
the crude rates of early (i.e., 90 days) ACS and MI for
patients having early ICA. This comparison was done in an
attempt to cull the patients with worsening symptom status
rgoing
r CCTA
p Value
ICA (n  1,896)
p Value
No REV
(n  955)
REV
(n  941)
0.0001 0.001
1.7% 0.7%
11.7% 9.8%
30.7% 26.6%
38.2% 37.9%
14.8% 21.6%
2.9% 3.4%
0.0001 41.3% 30.2% 0.0001
0.0001 0.0001
38.1% 32.1%
9.0% 8.5%
38.8% 37.6%
14.1% 21.8%
0.52 25.8% 25.8% 0.99
0.0001 0.0001
18.0% 12.6%
30.3% 27.3%
41.4% 45.1%
10.3% 15.0%
0.078 49.7% 51.2% 0.58
0.006 26.5% 26.5% 0.98
0.0001 52.3% 58.4% 0.009
0.0001 16.7% 23.0% 0.001
0.19 15.8% 19.4% 0.042
0.0001 62.3% 69.8% 0.29
0.0001 38.7% 41.1% 0.29Unde
Afte
)graphic angiography; ICA  invasive coronary angiography;
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November 13, 2012:2103–14 Computed Tomography Angiography as Gatekeeperfrom the overall early rates. Within 90 days, a total of 193 MI
and 259 ACS cases were identified.
Results
Clinical characteristics of the CONFIRM diagnostic
cohort. In this cohort, 46.2% had no CAD, 35.4% had
mild CAD, 11.3% had 1-vessel CAD, 4.6% had 2-vessel
CAD, and 2.5% had 3-vessel/left main CAD, respectively.
Table 1 depicts the comparative characteristics of the
patient cohort by CCTA findings. Patients with more
severe and extensive CAD were more often older and less
likely to be female, and cardiac risk factors were
prevalent.
Clinical characteristics of downstream ICA and REV. Pa-
tients referred for ICA and REV generally were older, less
likely to be female, and more likely to have presenting chest
pain symptoms (Table 2).
Cox proportional hazards estimating follow-up ICA and
REV. The cumulative rate of ICA at 36 months was 2.5%,
8.3%, 44.3%, 53.3%, and 69.4%, respectively, for none, mild
CAD, 1-vessel CAD, 2-vessel CAD, and 3-vessel/left main
CAD (Fig. 1, p  0.0001). Most instances of ICA (79.2%)
occurred within 90 days after the patient underwent CCTA.
0.0%
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First 3 Months of Follow-up
Figure 1 Post-CCTA Rates of Follow-Up ICAThe rate of ICA was similar for asymptomatic patients and
those presenting for evaluation of chest pain (unadjusted
p  0.15, adjusted p  0.41). A similar relationship for
downstream REV also was documented (Fig. 2). Of note,
the rate of late REV (i.e., 90 days) was 0.1%, 1.0%, 7.8%,
13.3%, and 26.0%, respectively, for none, mild, 1-vessel,
2-vessel, and 3-vessel CAD (p  0.0001).
Figure 3 breaks down the type of REV by the severity of
CAD. For patients with no CAD, 0.2% underwent percu-
taneous coronary intervention (PCI) and 0.1% underwent
coronary artery bypass graft (CABG). For patients with
mild CAD, 2.0% underwent PCI and 0.2% underwent
CABG. For patients with obstructive CAD, 28.5% under-
went PCI and 7.3% underwent CABG. The rates of PCI
and CABG were substantially higher for patients with
1-vessel to 3-vessel/left main CAD. The ICA/REV ratio,
representing the proportion of patients who underwent ICA
who were referred for REV, was 53.1%, 66.0%, and 80.1%
for persons with 1-vessel, 2-vessel, and 3-vessel/left main
CAD according to CCTA.
In an ROC analysis estimating ICA use, the area under
the curve was 0.85 (0.84 to 0.86) for CCTA-defined CAD
compared with 0.60 (0.58 to 0.61) for pre-test CAD
likelihood (p  0.0001). Similarly, the area under the curve
for REV was incrementally higher for CCTA-defined
.7 1.8 1.9 2 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 3
graphy (in years)
Mild CAD 
3.47 (2.88-4.18), p<0.0001
1 Vessel CAD
25.93 (21.79-30.86), p<0.0001
3 Vessel / Left Main CAD
46.72 (38.08-57.32), p<0.0001
3,864
2,449
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52
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279
87
32
2 Vessel CAD
32.91 (27.24-39.76), p<0.0001
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79.2% of invasive coronary angiograms occurred
within the first 3 months post-CCTA
*Please note that the figure 
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CAD likelihood (0.63, 0.62 to 0.65) variable (p  0.0001).
For the patients undergoing early ICA (i.e., 90 days),
igure 4 reports the frequency of preceding ACS or acute
I. For all CAD subsets, the frequency of preceding MI or
CS, before early ICA was low. For patients with no CAD,
preceding MI or ACS, before ICA, occurred in 4.2% and
.3% of patients, respectively.
ultivariable models estimating downstream ICA.
ignificant clinical estimators of downstream ICA included
amily history of CAD (p  0.0001), statin use (p 
0.0001), and typical angina (p  0.003) (Table 3). The
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Figure 2 Post-CCTA Rates of Follow-Up REV
Cumulative rate of follow-up coronary revascularization (REV) after coronary compu
tomographic angiography (CCTA). The number at risk is reported in Figure 1. CAD
0.2% 1.9%0.1% 0.2%
0%
10%
20%
30%
40%
50%
None Mild CAD
PCI CABG
p<0.0001 for both comparisons.
CAD
Figure 3 Follow-Up REV by CCTA-Defined CAD Extent
Follow-Up revascularization (percutaneous coronary intervention [PCI] or coronary a
by the number of vessels with coronary artery disease (CAD) by coronary computeadjusted odds of ICA increased from 27.0-fold to 42.1-fold
for patients with 1- to 3-vessel CAD (p 0.0001). Even for
patients with mild CAD, the adjusted odds ratio for ICA
was elevated 3.6-fold (p  0.0001). When examining
estimators of early ICA within 90 days after CCTA (Table 4),
the adjusted odds for ICA was elevated 3.8-fold, 4.6-fold,
and 4.2-fold, respectively, for 1-vessel, 2-vessel, and
3-vessel CAD (p  0.0001). Interestingly, for early ICA,
the adjusted odds ratio (1.3, 0.9 to 2.0) for mild CAD
was not significant (p  0.18). The median time to ICA
in patients with 50% stenosis was 2.0 years (25th to
75th percentile: 1.2 to 3.2 years). In patients with 50%
vascularization (in years)
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within 90 days.
For patients with 50% stenosis, advancing age (p 
0.0001) and typical angina (p  0.002) were significant
estimators of ICA (Table 5) over the duration of follow-up.
Additional estimators included the presence of mild CAD
in the left main coronary artery (p  0.0001), proximal left
anterior descending coronary artery (p  0.006), proximal
right coronary artery (p  0.0001), and proximal left
circumflex coronary artery (p  0.005), respectively. The
rate of downstream ICA was similar in obese and nonobese
patients without obstructive CAD (p  0.84).
A subset of 11,873 patients without CAD also had CAC
scoring results, including a 0 score in 54.7%, a 1 to 10 score
4.2%
(4/95)
1.1% 
(3/263) 0.8% 
(5/620)
1.6% 
(5/311)
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(11/21
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Figure 4 Follow-Up ICA After MI or ACS
The occurrence of early (90 days) preceding myocardial infarction (MI) or acute c
ease (CAD) defined by coronary computed tomographic angiography (CCTA). For ex
a preceding acute MI or ACS.
Multivariable Logistic Regression Predictorsof ICA Utilizati nTable 3 Multivariable Logistic R gression Predictorsof ICA Utilization
Odds
Ratio 95% CI
Wald
Chi-Square p Value
Age (by decade) 1.1 0.98–1.1 2.0 0.16
Family history of CAD 1.5 1.3–1.8 26.3 0.0001
Statin use 1.4 1.4–1.6 16.6 0.0001
Chest pain 11.0 0.012
Noncardiac 1.2 0.9–1.6 1.2 0.27
Atypical 0.9 0.8–1.2 0.0 0.95
Typical 1.4 1.1–1.7 8.7 0.003
CCTA CAD extent 1,140.0 0.0001
Mild CAD 3.6 2.8–4.5 106.9 0.0001
1-vessel 27.0 21.0–34.5 688.1 0.0001
2-vessel 36.5 27.1–49.0 569.3 0.0001
3-vessel/left main 42.1 29.4–60.2 419.1 0.0001
Model chi square  1,815.2; p  0.0001; model classification  88.1%. Coronary artery calcium
CAC) is significant in the aforementioned model when CCTA-defined CAD is not included. However,
AC scoring is no longer significant when added CCTA-defined CAD is added to the model (p 
.41).
CI  confidence interval; other abbreviations as in Table 2. hin 7.8%, an 11 to 99 score in 18.1%, a 100 to 399 score in
12.7%, and 400 score in 6.7%, respectively. The rate of
ICA increased with the CAC score (Fig. 5) and ranged
from 2.5% for a 0 score to 8.1% for patients with a score
400 (p  0.0001). Importantly, few of these patients with
vidence of CAC underwent REV (Fig. 5). For example,
nly 2.1% of patients with a CAC score 400 underwent
EV. When classifying ICA, the area under the ROC curve
or CCTA-defined CAD (0.84 [0.83 to 0.85]) was signif-
cantly higher than for CAC (0.72 [0.70 to 0.73], p 
.0001). A similar pattern of a higher ROC curve area for
CTA-defined CAD when compared with CAC also was
eported for REV.
lderly patient subset analysis. Compared to patients
65 years of age, the odds of referral to ICA was elevated
.0-fold for patients age 65 years and older (p  0.0001).
igure 6 reports the use of ICA and REV in elderly (65
ears of age) and nonelderly (65 years of age) patients. As
CAD: p=0.096
in CAD: p=0.56
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ry syndrome (ACS) and invasive coronary angiography (ICA) by coronary artery dis-
, of the 95 patients with no CAD who had an early ICA, only 4.2% and 6.3% had
Multivariable Logistic Regression Predictors of EarlyICA Use Within 90 Days of CCTATable 4 Multivari ble Logistic R gression Predictors of EarlyICA Use Within 90 Days of CCTA
Odds
Ratio 95% CI
Wald
Chi-Square p Value
Age (by decade) 0.9 0.8–0.97 6.4 0.011
Chest pain 6.2 0.10
Noncardiac 0.9 0.6–1.4 0.3 0.60
Atypical 1.4 1.0–1.8 4.6 0.032*
Typical 1.1 0.8–1.5 0.1 0.74
CCTA CAD extent 95.0 0.0001
Mild CAD 1.3 0.9–2.0 1.8 0.18
1-vessel 3.8 2.5–5.7 39.4 0.0001
2-vessel 4.6 2.8–7.3 39.4 0.0001
3-vessel/left main 4.2 2.5–7.1 29.6 0.0001 
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D
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ampleModel chi square  103.4; p  0.0001; model classification  79.6%. *Higher rate of family
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with the extent and severity of CCTA-defined CAD. In a
multivariable logistic regression model, when considering
other covariates from Table 3, age was not a significant
estimator of ICA use (p  0.65). However, in unadjusted
omparisons, the overall rate of ICA was higher in elderly
atients with mild and 1-vessel CAD (Fig. 6).
xploratory survival differences in ICA and REV by
CTA-defined CAD. We performed a stratified Cox
egression model to examine survival differences for patients
roceeding to ICA and REV after undergoing CCTA.
igure 7A reports the results of survival differences for
atients with 50% stenosis who underwent ICA and
EV. The observational survival results in patients with
50% stenosis reveal an adjusted relative hazard of 2.2 for
CA (p  0.011) and 1.6 (p  0.43) for REV, including
ovariate adjusted by symptoms and cardiac risk factors
Fig. 7A). Conversely, in patients with CCTA-defined
2.5%
3.3%
0.1% 0.0%
0%
1%
2%
3%
4%
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6%
7%
8%
9%
10%
0 1-10
ICA REV
p<0.0001 for both comparisons.
Figure 5 ICA and REV by Coronary Calcium Scores
Frequency of invasive coronary angiography (ICA) and coronary revascularization (R
Multivariable Logistic Regression Predictorsof Catheterization in 12,408 Patients WithCCTA Stenosis <50%
Table 5
Multivariable Logistic R gression Predictors
of Catheterization in 12,408 Patients With
CCTA Stenosis <50%
Odds
Ratio 95% CI
Wald
Chi-Square p Value
Age (per decade) 1.2 1.1–1.4 22.5 0.0001
Chest pain 12.6 0.006
Noncardiac 1.1 0.8–1.7 0.8 0.38
Atypical 0.9 0.8–1.2 0.2 0.66
Typical 1.6 1.2–2.2 9.5 0.002
Mild left main stenosis 1.7 1.3–2.1 14.5 0.0001
Mild proximal LAD stenosis 1.4 1.1–1.7 7.4 0.006
Mild proximal RCA stenosis 2.4 1.6–3.7 16.1 0.0001
Mild proximal LCX stenosis 1.5 1.1–1.9 8.0 0.005
Model chi square  177.8; p  0.0001; model classification  95.9%.
CCTA  coronary computed tomographic angiography; CI  confidence interval; LAD  left
anterior descending; LCX  left circumflex; RCA  right coronary artery.bstructive CAD, the relative hazard for ICA was 0.61 (p
.047) and for REV it was 0.63 (p  0.11) (Fig. 7B).
iscussion
he concept of a noninvasive test being applied as a
atekeeper to ICA has long been touted as a means of
electively identifying patients with a higher likelihood of
ndergoing CAD and reducing diagnostic workup costs
16–18). An effective gatekeeping function is defined when,
fter the test is performed, therapeutic management is
romptly targeted by the noninvasive test findings. Within
he CONFIRM registry, we observed that most instances
79%) of ICA use occurred within 90 days of CCTA,
upporting a CCTA-directed strategy that linked to near-
erm ICA and REV use. However, to be effective, this link
ust target appropriate patient candidates who benefit from
eferral for additional testing or treatment. We observed
hat the rates of ICA were low in patients with no to mild
AD, increased with the extent and severity of CCTA-
efined CAD and were as high as 44% to 69% for 1- to
-vessel/left main CAD (p  0.0001). Similarly, the ob-
erved REV rates for patients with 1- to 3-vessel/left main
AD ranged from 28% to 69% (p  0.0001).
When associations between diagnostic findings result in
argeted therapeutic intervention, improvements in CAD
utcomes may occur. We have seen recent examples when
ost-test management was ill-defined after noninvasive
esting (16,19–23) and, as such, the link between testing
nd outcomes often remains disconnected. In an exploratory
nalysis within the CONFIRM study, we observed trends
oward improved survival for patients with CAD as identi-
ed by CCTA who underwent ICA (p  0.047); despite
o mandate of specific post-CCTA therapy. This analysis
uggests that CCTA-defined CAD may enhance the
orrelation with ICA-defined CAD and improve targeted
%
6.2%
8.1%
2.0%
1.7%
2.1%
1-99 100-399 ≥400
 Score
coronary artery calcium (CAC) scores.4.8
1
CAC
EV) by
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From this observational assessment, the importance of
integrating ischemia with anatomic CAD to optimally
guide management and therapeutic risk reduction is
unclear (24).
From one recent report, the introduction of CCTA
resulted in a 45% reduction in the use of diagnostic ICA
(17). We reported a relatively low overall rate of ICA
(12.5%), suggesting that CCTA was operating as a filter,
with most ICA referrals limited to persons with obstructive
CAD. In a similar report by Tandon et al. (25), only 10.6%
of patients undergoing CCTA were referred for ICA.
However, a recent report using claims data revealed higher
ICA rates (22.9% at 6 months) after CCTA compared with
the rate of 12.5% at 3 years for the CONFIRM study (26).
From the SPARC (Study of Myocardial Perfusion and
Coronary Anatomy Imaging Roles in CAD) registry, in a
smaller subset of 590 patients with a high frequency of prior
stress testing, 13.2% of patients who underwent CCTA
were referred for ICA at 90 days (27). Given that there is no
CMS national coverage decision on the use of CCTA, the
prior data analyses may include unique test indications, such
as a prior indeterminate stress test, which may have altered
the likelihood of referral for ICA. Additionally, Bayesian
theory would dictate that referral probabilities would be
higher after a second diagnostic procedure when compared
with the ICA likelihood after an index diagnostic workup
with CCTA alone.
Although we observed a relatively low rate of downstream
ICA in patients with no CAD (2.5%) to mild CAD (8.3%),
we hypothesized that compromised image quality or re-
duced interpretive confidence may have prompted referral to
ICA in this cohort with no CAD to mild CAD in the early
application of CCTA use; particularly in the presences of
2.1%
6.8%
3.1%
8.5%
0%
10%
20%
30%
40%
50%
60%
70%
None Mild CAD
<65 years ≥65 years
p<0.0001 for both comparisons.
p=0.071
p=0.022
Figure 6 Follow-Up ICA by Age
Cumulative rate of follow-up invasive coronary angiography (ICA) in elderly (65 yedense coronary calcium. Given the documented challengesin interpretation in the setting of CAC, we explored ICA
use after CCTA by an increasing Agatston score. We
reported in patients with nonobstructive CAD, we reported
an increased utilization of ICA for patients with high-risk
CAC scores, such that nearly 1 in 14 patients with a CAC
score of 400 or higher were referred for ICA. From 1 recent
survey, the results of CCTA were reported to improve risk
reclassification in only 58% of patients (28), which may
explain some of the imprecise management observed in the
CONFIRM subset of patients with no CAD to mild CAD.
These findings of ICA use in patients with nonobstruc-
tive CAD represent opportunities for improvement and
efficiency in CCTA-guided management. In 1 previous
report, positive CCTA findings were associated with addi-
tional testing (p  0.0001) and REV (p  0.0001) within
90 days (29). Although no guided therapy or management
trials after use of CCTA have been performed, the prog-
nostic findings from prior CONFIRM (8,10,11) and other
series (14,30–33) support the hypothesis that these patients
with 50% stenosis are at lower risk of major adverse CAD
events. Of note, in our exploratory survival analysis, we
observed an elevated hazard (2.2-fold) for death for patients
with mild CAD who underwent ICA (p  0.011). More-
over, current guidelines for stable ischemic heart disease
(34) limit ICA use to patients with high-risk findings on
diagnostic testing. With increased awareness of the low
event rates associated with mild CAD findings, CCTA-
guided care may become more efficient and effective if
medical management of patients with 50% stenosis is
applied. In several cases, early ICA was preceded by an
ACS, which is consistent with guideline-accepted best
practices (34). However, most early ICA use was not event
driven.
Several previous series have examined the frequency of
%
53.4%
64.6%
40.0%
48.9%
64.6%
sel CAD 2 Vessel CAD3 Vessel / Le Main CA
.043
p=0.24
p=0.99
nd nonelderly (65 years of age) patients. CAD  coronary artery disease.44.9
1 Ves
p=0
ars) adownstream invasive procedural use in patients with and
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report with a mean duration of follow-up of 1.4 years, no
patients with no CAD to mild CAD underwent REV (35).
Our results further examine the impact of near- and
long-term ICA use in this cohort with mild CAD. In this
subset of patients with mild CAD, a novel finding reported
herein noted that the adjusted odds of early ICA within 90
days was not statistically significant (p  0.18). For
longer term follow-up, however, the presence of mild
CAD, in particular in the setting of a proximal lesion,
increased the adjusted odds of a downstream ICA (p 
0.0001). It remains plausible that the CCTA findings of
mild CAD might have increased the relative odds of
undergoing ICA over the length of follow-up influencing
the consideration on the part of physicians that disease
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Figure 7 Cumulative Survival by ICA and REV in Patients With
(A) Observational comparison of survival for 5,380 patients with mild coronary art
sive coronary angiography (ICA) and coronary revascularization (REV). (B) Observat
coronary computed tomographic angiography ICA and coronary REV. Model covariaprogression may have occurred in these patients. Thus, itis likely that CCTA may increase longer term down-
stream costs for patients with mild CAD, and in partic-
ular for the cohorts with proximal, mild CAD. Further
research is needed in this cohort to examine clinical
strategies to optimize risk detection and target treatments
for this cohort with nonobstructive CAD, and in partic-
ular to identify strategies curbing unnecessary down-
stream ICA use whenever possible.
Study limitations. We used several analyses to explore the
consequences of reported overestimation of the percentage
of stenosis by CCTA; but the observational nature of this
registry causality cannot be determined. Detailed informa-
tion on the target lesion or graft would aid in delineating the
accuracy of CCTA to identify revascularizable disease. The
role of nonobstructive atherosclerosis and progressive dis-
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Moreover, our database did not include the information on
previous stress test results. The inclusion of stress testing
results could have added further to our understanding of the
role of anatomic and functional data in the decision to
undergo ICA and REV. We included a nonrandom obser-
vational comparison of the effectiveness of ICA and REV in
terms of survival reduction. This analysis should be viewed
within the context of selection bias and other unadjusted
factors that contribute to the reported findings. Importantly,
this analysis is exploratory and should be viewed as such.
Conclusions
These data support the concept that CCTA may be used
effectively as a gatekeeper to ICA. Patients with no or mild
CAD were uncommonly referred to ICA, while in those with
more extensive and severe obstructive CAD, a gradient in-
crease in ICA and REV use was observed. Optimal targeting
of high-risk patients with CAD based on CCTA may facilitate
targeted intervention and improved outcome of patients un-
dergoing a diagnostic workup for suspected CAD. The impli-
cations of CCTA as an effective gatekeeper is that direct
referral for ICA may be circumvented in the large proportion
of patients with no to mild CAD. However, it also appears
from the CONFIRM data that further reductions in ICA use
may be realized in patients with no to mild CAD who may be
managed medically unless worsening clinical status ensues
during follow-up. Strategies should be targeted to reduce ICA
use in patients with nonobstructive CAD and to foster initial
medical management approaches, with referral for ICA limited
to patients with refractory symptoms.
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